291 related articles for article (PubMed ID: 25420104)
21. Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region.
Nicely NI; Dennison SM; Spicer L; Scearce RM; Kelsoe G; Ueda Y; Chen H; Liao HX; Alam SM; Haynes BF
Nat Struct Mol Biol; 2010 Dec; 17(12):1492-4. PubMed ID: 21076400
[TBL] [Abstract][Full Text] [Related]
22. The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.
Huarte N; Lorizate M; Maeso R; Kunert R; Arranz R; Valpuesta JM; Nieva JL
J Virol; 2008 Sep; 82(18):8986-96. PubMed ID: 18596094
[TBL] [Abstract][Full Text] [Related]
23. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
[TBL] [Abstract][Full Text] [Related]
24. Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.
Banerjee S; Shi H; Habte HH; Qin Y; Cho MW
Virology; 2016 Mar; 490():17-26. PubMed ID: 26803471
[TBL] [Abstract][Full Text] [Related]
25. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.
Ofek G; Zirkle B; Yang Y; Zhu Z; McKee K; Zhang B; Chuang GY; Georgiev IS; O'Dell S; Doria-Rose N; Mascola JR; Dimitrov DS; Kwong PD
J Virol; 2014 Mar; 88(5):2426-41. PubMed ID: 24335316
[TBL] [Abstract][Full Text] [Related]
26. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.
Shen X; Parks RJ; Montefiori DC; Kirchherr JL; Keele BF; Decker JM; Blattner WA; Gao F; Weinhold KJ; Hicks CB; Greenberg ML; Hahn BH; Shaw GM; Haynes BF; Tomaras GD
J Virol; 2009 Apr; 83(8):3617-25. PubMed ID: 19193787
[TBL] [Abstract][Full Text] [Related]
27. Functional Optimization of Broadly Neutralizing HIV-1 Antibody 10E8 by Promotion of Membrane Interactions.
Rujas E; Leaman DP; Insausti S; Ortigosa-Pascual L; Zhang L; Zwick MB; Nieva JL
J Virol; 2018 Apr; 92(8):. PubMed ID: 29386285
[TBL] [Abstract][Full Text] [Related]
28. Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.
Habte HH; Banerjee S; Shi H; Qin Y; Cho MW
Virology; 2015 Dec; 486():187-97. PubMed ID: 26454663
[TBL] [Abstract][Full Text] [Related]
29. Selection and immune recognition of HIV-1 MPER mimotopes.
Wieczorek L; Peachman K; Steers N; Schoen J; Rao M; Polonis V; Rao V
Virology; 2020 Nov; 550():99-108. PubMed ID: 32980676
[TBL] [Abstract][Full Text] [Related]
30. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization.
Kim M; Sun ZY; Rand KD; Shi X; Song L; Cheng Y; Fahmy AF; Majumdar S; Ofek G; Yang Y; Kwong PD; Wang JH; Engen JR; Wagner G; Reinherz EL
Nat Struct Mol Biol; 2011 Oct; 18(11):1235-43. PubMed ID: 22002224
[TBL] [Abstract][Full Text] [Related]
31. Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates.
Wu C; Raheem IT; Nahas DD; Citron M; Kim PS; Montefiori DC; Ottinger EA; Hepler RW; Hrin R; Patel SB; Soisson SM; Joyce JG
Proc Natl Acad Sci U S A; 2024 May; 121(22):e2317230121. PubMed ID: 38768344
[TBL] [Abstract][Full Text] [Related]
32. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
[TBL] [Abstract][Full Text] [Related]
33. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.
Ye L; Wen Z; Dong K; Wang X; Bu Z; Zhang H; Compans RW; Yang C
PLoS One; 2011; 6(5):e14813. PubMed ID: 21625584
[TBL] [Abstract][Full Text] [Related]
34. Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.
Xu H; Song L; Kim M; Holmes MA; Kraft Z; Sellhorn G; Reinherz EL; Stamatatos L; Strong RK
J Virol; 2010 Jan; 84(2):1076-88. PubMed ID: 19906921
[TBL] [Abstract][Full Text] [Related]
35. Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization.
Kim AS; Leaman DP; Zwick MB
PLoS Pathog; 2014 Jul; 10(7):e1004271. PubMed ID: 25058619
[TBL] [Abstract][Full Text] [Related]
36. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.
Lai RP; Hock M; Radzimanowski J; Tonks P; Hulsik DL; Effantin G; Seilly DJ; Dreja H; Kliche A; Wagner R; Barnett SW; Tumba N; Morris L; LaBranche CC; Montefiori DC; Seaman MS; Heeney JL; Weissenhorn W
J Biol Chem; 2014 Oct; 289(43):29912-26. PubMed ID: 25160627
[TBL] [Abstract][Full Text] [Related]
37. Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion.
Hu B; Liao HX; Alam SM; Goldstein B
PLoS Comput Biol; 2014 Jan; 10(1):e1003431. PubMed ID: 24499928
[TBL] [Abstract][Full Text] [Related]
38. Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.
Diomede L; Nyoka S; Pastori C; Scotti L; Zambon A; Sherman G; Gray CM; Sarzotti-Kelsoe M; Lopalco L
J Virol; 2012 Apr; 86(8):4129-38. PubMed ID: 22301151
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies.
Wang J; Tong P; Lu L; Zhou L; Xu L; Jiang S; Chen YH
PLoS One; 2011 Mar; 6(3):e18233. PubMed ID: 21483871
[TBL] [Abstract][Full Text] [Related]
40. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine.
Wahome N; Pfeiffer T; Ambiel I; Yang Y; Keppler OT; Bosch V; Burkhard P
Chem Biol Drug Des; 2012 Sep; 80(3):349-57. PubMed ID: 22650354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
